Hematologic Malignancy Targeted Drugs Market Size, Share, and Industry Analysis, By Drug Class (BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, Proteasome inhibitors, IMiDs & CELMoDs, CD20/Other Targeted mAbs, CAR-T Cell Therapy, Bispecific Antibodies, and Others), By Disease Indication (Multiple Myeloma, CLL/SLL, Non-Hodgkin Lymphoma, Acute Leukemias, and Other Hematologic Malignancies), By Distribution Channel (Hospital Pharmacies, Retail/Specialty Pharmacies, and Online Pharmacies), and Regional Forecast till 2034

The hematologic malignancy targeted drugs market was valued at USD 38.00 billion in 2025. The market is projected to grow from USD 41.16 billion in 2026 to USD 78.00 billion by 2034, exhibiting a CAGR of 8.3% during the forecast period.

The hematologic malignancy targeted drugs market includes precision therapies used to treat blood cancers such as leukemia, lymphoma, multiple myeloma, and related disorders by targeting specific molecular or cellular pathways. The market is anticipated to witness significant growth over the forecast period as treatment for hematologic cancers shifts toward selective approaches, including BTK inhibitors, BCL-2 inhibitors, FLT3 inhibitors, monoclonal antibodies, bispecific antibodies, and CAR-T/cell-based targeted therapies. The market growth is also supported by rising demand for relapse-line treatments, increasing biomarker-driven therapy selection, and continued strategic activity by biotechnology and pharmaceutical companies collaborating to strengthen pipelines, expand indications, and build long-term leadership in hematology.

• For instance, in January 2025, AbbVie Inc. collaborated with Simcere Pharmaceutical Group Ltd to develop SIM0500, a trispecific antibody candidate for relapsed or refractory multiple myeloma. Such strategic collaborations strengthen next-generation targeted therapy pipelines in hematologic malignancies and boost market growth.

Furthermore, funding initiatives, research and development, expanding pipeline portfolios, and new product launches by major companies strengthen their market position and support the overall market growth.

Hematologic Malignancy Targeted Drugs Market Driver

Shift Toward Precision Medicine and Expanding Approvals of Targeted Therapies Driving Market Growth

A key factor driving the global hematologic malignancy targeted drugs market is the shift toward precision medicine and the expanding approvals of targeted therapies. As treatment for blood cancers is moving steadily toward more selective, biomarker-based, and disease-specific therapies, the demand for targeted drugs for hematologic malignancies also rises. targeted drugs improve response rates and help manage difficult relapsed or refractory cases; expanding their use increases across leukemia, lymphoma, and multiple myeloma treatment pathways. Also, continued regulatory approvals and label expansions are bringing newer targeted options into clinical practice, broadening the patient pool eligible for treatment and supporting greater market adoption. These factors provide more treatment choices, better clinical confidence, and stronger commercial uptake across major markets.

• For instance, in April 2025, F. Hoffmann-La Roche Ltda announced that the European Commission approved Columvi (glofitamab) in combination with GemOx for adults with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant. Roche stated that the approval was supported by Phase III STARGLO study results showing a 41% reduction in the risk of death versus rituximab plus chemotherapy, highlighting how new targeted therapy approvals are expanding the market.

Download Free sample to learn more about this report.

For instance, in 2025, the National Cancer Institute estimated that 2,041,910 new cancer cases would occur. The increasing prevalence of cancer is driving demand for hematologic malignancy-targeted drugs in cancer treatment regimens.

Hematologic Malignancy Targeted Drugs Market Restraint

Adverse Events and Safety Monitoring Requirements Limiting Treatment Adoption Hampering Market Growth

The global hematologic malignancy targeted drugs market faces a restraint, as many advanced targeted therapies are associated with serious adverse events that require close monitoring and specialized care. When treatment can lead to complications such as cytokine release syndrome, neurologic toxicities, infections, or prolonged safety observation, hospitals and physicians become more cautious in adoption, particularly in community settings with limited infrastructure. These factors increase the overall burden on treatment centers, raise the cost of care delivery, and can delay patient access even when the drug shows strong efficacy. This results in a higher safety risk and more intensive monitoring requirements, creating operational and clinical barriers that slow broader market penetration of targeted therapies.

• For instance, in March 2025, NIH published a systematic review titled 'Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma' on bispecific antibodies in B-cell non-Hodgkin lymphoma and multiple myeloma, reporting that these therapies are associated with distinct immune-related toxicities that affect morbidity and mortality. When targeted therapies carry toxicity risk, providers need closer monitoring, supportive care, and more specialized administration settings, which can restrict broader adoption and slow commercial expansion.

Hematologic Malignancy Targeted Drugs Market Opportunity

Rising Development of Next-Generation Bispecific Antibodies and CAR-T Therapies Creating New Market Expansion Opportunities

The significant growth opportunity for targeted drugs in global hematologic malignancies lies in the development of next-generation bispecific antibodies and CAR-T therapies. These therapies are expanding treatment options for patients who have limited benefit from conventional therapies. As these advanced therapies show deeper responses, longer remission periods, and broader use across relapsed or refractory lymphoma, leukemia, and myeloma settings, physician confidence and patient eligibility continue to improve. At the same time, newer product formats, additional indications, and movement into earlier treatment lines are helping companies widen the commercial potential of targeted hematology drugs. Underscoring these growth opportunities, key companies are focusing on new product launches and their subsequent regulatory approvals to commercialize their growth potential.

• For instance, in March 2025, Bristol Myers Squibb received approval from the European Commission for Breyanzi for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. The company stated that 97.1% of patients responded in the TRANSCEND FL trial and 94.2% achieved complete response, showing how expanding CAR-T approvals into additional hematologic indications can open new commercial opportunities and support future market growth.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Blood Cancers, By Key Countries/Region, 2025
• New Product Launches, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• Regulatory & Reimbursement Scenarios, By Key Countries/Regions

Analysis by Drug Class

Based on drug class, the global hematologic malignancy-targeted drugs market is segmented into BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, Proteasome inhibitors, IMiDs & CELMoDs, CD20/other targeted mAbs, CAR-T cell therapy, bispecific antibodies, and others.

Among these, the IMiDs & CELMoDs segment is estimated to hold a leading share. This segment is expected to dominate the market share as multiple myeloma remains one of the largest and most commercially important areas of treatment for hematologic malignancies. These IMiDs are deeply embedded in standard therapy across different lines of treatment. As these drugs are used in combination regimens, maintenance settings, and relapsed disease management, they continue to generate broad and recurring demand across a large treated patient pool. This results in wider use across treatment pathways, leading to higher prescription volume and stronger revenue contribution, which supports the segment's leading market position. Underscoring these factors, key companies are focusing on research initiatives to develop new products and expand their offerings in the segment.  

• For instance, in September 2025, Bristol Myers Squibb announced that its Phase 3 EXCALIBER-RRMM study showed iberdomide (a CELMoD) in combination with standard therapies achieved a statistically significant improvement in MRD negativity rates in relapsed or refractory multiple myeloma, highlighting continued investment and commercial momentum in the IMiD/CELMoD class.

Analysis by Disease Indication

Based on disease indication, the global hematologic malignancy targeted drugs market is segmented into Multiple myeloma, CLL/SLL, Non-Hodgkin lymphoma, Acute leukemias, and Other hematologic malignancies.

Among these, the multiple myeloma segment is anticipated to hold a leading market share. High share is attributed to the segment, as it has one of the broadest targeted treatment landscapes, including proteasome inhibitors, IMiDs/CELMoDs, monoclonal antibodies, bispecifics, and CAR-T therapies. As more targeted options become available for relapsed or refractory patients, physicians have more opportunities to sequence and combine therapies over a longer treatment journey. This increases treatment intensity and market value per patient, making multiple myeloma the strongest revenue-generating indication in the market. Also, key product launches and regulatory approvals will fuel their segmental growth. 

• For instance, in July 2025, Regeneron announced that the U.S. FDA granted accelerated approval to Lynozyfic (linvoseltamab-gcpt) for the treatment of relapsed or refractory multiple myeloma. The product achieved an overall response rate of 70% and a complete response rate of 45% in heavily pretreated patients, underscoring how continued approvals are expanding the targeted treatment base in multiple myeloma.

Analysis by Distribution Channel

Based on distribution channel, the market is segmented into hospital pharmacies, retail/specialty pharmacies, and online pharmacies.

Hospital pharmacies are projected to dominate the market by distribution channel. A large share of advanced hematologic malignancy-targeted therapies, especially infused biologics, bispecific antibodies, and CAR-T treatments, require specialist supervision, step-up dosing, adverse-event monitoring, and administration in hospital-based cancer centers. As these therapies are complex and frequently need coordinated clinical support, dispensing and treatment flow remain concentrated in hospital settings. These factors collectively result in greater reliance on hospital-based handling and administration, making hospital pharmacies the leading distribution channel.   

• For instance, in June 2025, Bristol Myers Squibb announced that the U.S. FDA approved streamlined monitoring requirements and removal of REMS programs for Breyanzi and Abecma. The company noted that only about 2 in 10 eligible patients currently receive cell therapy, reflecting the concentration of administration and monitoring in specialized treatment centers, which supports the dominance of hospital pharmacies in this market.

Regional Analysis

Request for Customization   to gain extensive market insights.

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 42.0 % of the global hematologic malignancy targeted drugs market in 2025. The strong growth in North America is driven by the rising prevalence of cancer and the growing demand for supportive care drugs. Also, the region has a high diagnosed burden of leukemia, lymphoma, and myeloma, along with strong access to biomarker testing, specialist cancer centers, and premium-priced targeted therapies. As new hematologic cancer drugs are approved, physicians gain greater confidence in using targeted regimens earlier and across more treatment lines, thereby directly increasing market uptake. Emphasizing these factors, key companies are also advancing their offerings through strategic partnerships and boosting market growth.

• For instance, in December 2025, Bristol Myers Squibb announced that the U.S. FDA approved Breyanzi as the first and only CAR-T cell therapy for adults with relapsed or refractory marginal zone lymphoma (MZL). Breyanzi delivered 95.5% response rates in the MZL cohort of TRANSCEND FL, making this a strong North America example of regulatory progress in targeted hematologic malignancy therapy. Such developments drive the market growth in the region.

Europe is expected to grow at a significant CAGR during the forecast period. The growth in Europe is attributed to a large cancer burden and a well-established regulatory pathway for oncology medicines. These factors support broader availability of new hematologic targeted drugs across EU markets. As key regulatory bodies continue to authorize newer cancer therapies, treatment options expand for relapsed and refractory patients strengthening the adoption of targeted drugs in routine hematology care. Additionally, favorable government regulations and strategic partnerships expand distribution and access, reducing friction in options and boosting market growth.

• For example, in April 2025, Roche announced that the European Commission approved Columvi (glofitamab) plus GemOx for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant. Roche stated that this was the first bispecific antibody regimen available in Europe for this setting, making it a strong market development opportunity in Europe. in a key European market and thereby fueling market growth.

Asia Pacific is expected to grow at a stable CAGR during the forecast period. The market is growing in the region due to growing incidence of leukemia and non-Hodgkin lymphoma, creating a large addressable patient pool. As diagnoses improve and major countries in the region expand access to advanced oncology care and targeted treatments, demand for hematologic malignancy drugs continues to rise, supporting faster market expansion than in many mature regions. Also, expanding the pipeline by key companies reinforces the growth potential.

• For instance, in March 2026, HUTCHMED (China) Limited initiated a registrational Phase III clinical trial of HMPL‑760 in combination with R‑GemOx (rituximab, gemcitabine, and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma in China. Such developments are driving the region's growth.

Key Players covered

The global hematologic malignancy-targeted drug market is consolidated, with a few players capturing significant market share. The report includes the profiles of the following key players.

• Johnson & Johnson (U.S.)
• Bristol Myers Squibb (U.S.)
• AbbVie Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• AstraZeneca (U.K)
• Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• HUTCHMED (Hong Kong)
• Regeneron Pharmaceuticals Inc (U.S.)

Key Industry Developments

• March 2026: Novartis AG agreed with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a next-generation approach for the treatment of patients with HR+/HER2- breast cancer and potentially other solid tumor indications.
• November 2025: Takeda Pharmaceuticals U.S.A., Inc showcased positive data at ASH 2025, highlighting advances across its hematologic cancer pipeline, including updated Phase 2 results for elritercept in anemia associated with myelodysplastic syndromes (MDS) and myelofibrosis (MF).